Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.

@article{Richards2013ResultsOD,
  title={Results of docetaxel plus oxaliplatin (DOCOX) ± cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study.},
  author={D. Richards and D. Kocs and A. Spira and A. David McCollum and S. Diab and L. I. Hecker and A. Cohn and F. Zhan and L. Asmar},
  journal={European journal of cancer},
  year={2013},
  volume={49 13},
  pages={
          2823-31
        }
}
BACKGROUND Patients with advanced adenocarcinoma of the gastroesophageal junction/stomach are treated by combination chemotherapy, with minimal improvements in survival. We evaluated adding cetuximab to combination chemotherapy in these patients. METHODS The primary objective was progression-free survival. Secondary objectives were response rate, time to response, duration of response and safety. Treatment Arm 1: docetaxel+oxaliplatin (DOCOX)=docetaxel 60 mg/m(2) plus oxaliplatin 130 mg/m(2… Expand
DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma
TLDR
This single-arm trial demonstrates that the combination of docetaxel and oxaliplatin yields promising results for the treatment of advanced pancreatic ductal adenocarcinoma patients, and could be an interesting option for patients who received gemcitabine as first line treatment for metastatic pancreatic cancer. Expand
A meta-analysis of clinical trials over regimens with or without cetuximab for advanced gastric cancer patients.
TLDR
Adding cetuximab to chemotherapy does not improve OS or DCR compared with chemotherapy alone, but cetUXimab-containing combination chemotherapy can reduce the risk of neutropenia. Expand
Efficacy and toxicity of nimotuzumab combined with radiotherapy in elderly patients with esophageal squamous cell carcinoma.
TLDR
The toxicity of combined nimotuzumab with RT in elderly patients with esophageal cancer was tolerable, however, due to limitations associated with the retrospective nature of this study, the limited number of enrolled cases and the epidermal growth factor receptor expression determination prior to treatment, the efficacy of this treatment modality requires further investigation. Expand
The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysis
TLDR
It is indicated that the addition of an anti-EGFR agent to chemotherapy conveys no additional benefit for patients with advanced esophago-gastric adenocarcinoma. Expand
The relative efficacy and safety of targeted agents used in combination with chemotherapy in treating patients with untreated advanced gastric cancer: a network meta-analysis
TLDR
Trastuzumab was recommended as the optimal targeted agent combined with chemotherapy for gastric cancer patients and compared with other analyzed treatments, ramucirumab is outstanding in survival outcomes. Expand
Genomic analysis of response to neoadjuvant chemotherapy in esophageal adenocarcinoma
TLDR
Lower mutation burden, higher chromosomal instability and specific copy number alterations are associated with resistance to NAC in EAC. Expand
Efficacy and safety of target combined chemotherapy in advanced gastric cancer: a meta-analysis and system review
TLDR
The target combined chemotherapy represented a better overall survival benefit and treatment efficiency and higher incidence of some grade 3–4 adverse events than the traditional chemotherapy for patients with unresectable advanced or recurrence gastric cancer. Expand
Evaluation of short‐term effectiveness of eight targeted agents combined with chemotherapy for treating esophageal‐gastric junction adenocarcinoma: A network meta‐analysis
TLDR
Cluster analysis results indicated that ramucirumab plus chemotherapy might be the optimal treatment for EGJA amongst the nine treatment regimens, which provided clinical guidance for clinicians in the treatment of EGJA. Expand
Anti-epidermal growth factor receptor-targeted therapy in upper gastrointestinal tract cancers: a meta-analysis
TLDR
Overall survival was apparently lower in patients without metastasis, and PFS was apparently improved in patients with squamous cell carcinoma of the esophagus and esophagogastric junction. Expand
Targeted Therapy in Advanced Gastric Cancer: An Updated Review Keywords: Gastric cancer; Gastric adenocarcinoma; Targeted
TLDR
Currently available knowledge and clinical data for some of the most common signaling targets and their respective therapeutic trials for gastric cancer are outlined and summarized. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction.
TLDR
DOCOX produced manageable toxicity in patients with advanced GC and AGEJ, and the confirmed RR of 36%, CBR of 40%, and median survival of 8.5 months are encouraging and comparable to standard front-line regimens. Expand
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
TLDR
Adding docetaxel to CF significantly improved TTP, survival, and response rate in gastric cancer patients, but resulted in some increase in toxicity. Expand
Cetuximab as Second-Line Therapy in Patients with Metastatic Esophageal Adenocarcinoma: A Phase II Southwest Oncology Group Study (S0415)
  • P. Gold, B. Goldman, +4 authors C. Blanke
  • Medicine
  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2010
TLDR
The 6-month overall survival rate of 36% observed on this study failed to meet the primary survival objective, and cetuximab alone cannot be recommended in the second-line treatment of metastatic esophageal cancer. Expand
Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus.
  • A. Mauer, E. Kraut, +4 authors E. Vokes
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2005
TLDR
The combination of oxaliplatin, leucovorin, and fluorouracil shows significant anti-tumor activity and a favorable toxicity profile in patients with metastatic carcinoma of the esophagus. Expand
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
TLDR
The combination of cetuximab and FOLFIRI is active in gastric and GEJ adenocarcinoma, and the higher toxicity appears to be limited to neutropenia. Expand
Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer
TLDR
The progression-free rates confirm that cetuximab q2w in combination with irinotecan is an option, and is as active and safe as the standard weekly regimen. Expand
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients
TLDR
Responsibility rate (RR), TTP and OS were comparable with those of other oxaliplatin-based regimens, suggesting a role for this combination in gastric cancer. Expand
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
TLDR
Biweekly fluorouracil, folinic acid, and oxaliplatin is active and well-tolerated in patients with advanced gastric cancer, and response rates, time to progression, and overall survival were comparable to those achieved with other combination chemotherapy regimens, including FOLFOX6, with significantly less toxicity. Expand
A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).
TLDR
Addition of P to EOC chemotherapy was associated with worsening of OS in an unselected advanced OGA population, which may be in part due to lowered doses of O and C in the mEOC+P regimen. Expand
A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma.
TLDR
Although well tolerated, cetuximab administered as a single agent had minimal clinical activity in patients with metastatic esophageal and gastric adenocarcinoma. Expand
...
1
2
3
4
...